These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8290969

  • 21. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 22. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Dec; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 23. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 24. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct 15; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 25. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S, Feusner J, Seibel N, Weiman M, Aplenc R, Gerbing R, Alonzo TA.
    J Clin Oncol; 2004 Jan 01; 22(1):150-6. PubMed ID: 14701777
    [Abstract] [Full Text] [Related]

  • 26. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 01; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 27. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V.
    Ann Hematol; 2005 Nov 01; 84(12):792-5. PubMed ID: 16047203
    [Abstract] [Full Text] [Related]

  • 28. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Nov 01; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 29. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Nov 01; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 30. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S, Roovers E, Muus P, Schaap N, de Witte T.
    Bone Marrow Transplant; 1998 Jul 01; 22(1):13-9. PubMed ID: 9678790
    [Abstract] [Full Text] [Related]

  • 31. Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
    Isnard F, Guiguet M, Laporte JP, Zunic P, Elloumi M, Chéron N, Deloux J, Van Den Akker J, Lesage S, Fouillard L, Aoudjhane M, Lopez M, Douay L, Gorin NC, Najman A.
    Bone Marrow Transplant; 2001 May 01; 27(10):1045-52. PubMed ID: 11438819
    [Abstract] [Full Text] [Related]

  • 32. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O'Connell MJ, Paietta E.
    Leukemia; 1992 May 01; 6 Suppl 2():116-9. PubMed ID: 1578910
    [Abstract] [Full Text] [Related]

  • 33. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.
    J Clin Oncol; 2005 Jan 20; 23(3):482-93. PubMed ID: 15534356
    [Abstract] [Full Text] [Related]

  • 34. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
    de la Rubia J, Sanz GF, Martín G, Sempere A, Picón I, Carral A, Larrea L, Martínez J, Soler MA, Bonanad S, López F, Jarque I, Sanz MA.
    Bone Marrow Transplant; 1996 Dec 20; 18(6):1167-73. PubMed ID: 8971390
    [Abstract] [Full Text] [Related]

  • 35. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb 20; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 36. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
    Pashko S, Jacobs J, Santorsa J.
    Clin Ther; 1991 Feb 20; 13(3):353-60. PubMed ID: 1954636
    [Abstract] [Full Text] [Related]

  • 37. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
    Hołowiecki J, Krzemień S, Rudzka E, Krawczyk M, Wojnar J, Hołowiecka B, Wacławik A, Wojciechowska M, Kachel L, Cedrych I.
    Acta Haematol Pol; 1994 Feb 20; 25(3):221-30. PubMed ID: 7992594
    [Abstract] [Full Text] [Related]

  • 38. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
    De La Serna J, Francisco Tomás J, Solano C, García de Paredes ML, Campbell J, Grande C, Diaz-Mediavilla J.
    Leuk Lymphoma; 1997 Apr 20; 25(3-4):365-72. PubMed ID: 9168446
    [Abstract] [Full Text] [Related]

  • 39. Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
    Siddiqui T, Durkin WJ, Conley NS, Doughney KB, Favis GR, Weiss R, Smith AE.
    J Fla Med Assoc; 1994 Jul 20; 81(7):475-7. PubMed ID: 7964574
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.
    Amadori S, Giona F, Giuliano M, Moleti ML, Pession A, Rolla M, Rondelli R, Testi AM, Mandelli F.
    Leukemia; 1992 Jul 20; 6 Suppl 2():44-7. PubMed ID: 1578940
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.